Biotech Startups
9,603 companies tagged Biotech, with their investors and founders.
GlycoEra develops glycan-based therapeutics, applying glycoengineering technology to create biologic drugs. The company operates in the biotech and drug development space.
6 investors
Gordian Biotechnology develops therapies aimed at treating age-related diseases to extend healthy lifespan. It operates in the biotechnology and longevity space.
6 investors
Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an investigational drug candidate for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
6 investors
Gourmey produces cultivated meat, with its first product being a lab-grown foie gras aimed at fine-dining chefs and restaurants. The company develops sustainable alternatives to conventional meat production for the culinary and food industry.
6 investors
Healionics develops STARgraft, a synthetic vascular graft built on its STAR biomaterial scaffold that resists occlusion and infection to create a reliable bloodstream access site for kidney dialysis patients. The device has received FDA Breakthrough Device designation and targets the treatment of kidney failure through dialysis.
6 investors
HistoSonics develops histotripsy technology, a non-invasive method that uses focused sound energy to destroy targeted tissue, offered as a medical device for physicians and their patients. The company markets its technology to healthcare providers internationally.
6 investors
Iantrek develops micro-interventional ophthalmic surgical technologies focused on enhancing total outflow through the uveoscleral pathway to treat glaucoma. Its commercialized bio-interventional solutions are used by surgeons in glaucoma patient care.
6 investors
Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies. The company is building on research from academic institutions including Dana Farber Cancer Institute and MIT.
6 investors
Infinitopes develops immunotherapy treatments for cancer, focusing on immune-oncology and antigen discovery solutions aimed at improving patient outcomes and affordability in cancer care.
6 investors
This page is a thought-leadership essay by Teymour Boutros-Ghali of Bold Capital Partners arguing that venture investors and foundations should fund the commercialization phase of health-equity-focused life science companies using non-dilutive capital. It is an opinion article rather than a description of a specific product or company.
6 investors
insitro is a drug discovery and development company that uses machine learning and cellular data to identify therapeutic insights and accelerate the creation of new medicines. The company serves patients and pharmaceutical development by integrating in vitro lab data with human clinical data to decode biology and unlock transformative treatments.
6 investors
KaloCyte develops ErythroMer, a dried, shelf-stable artificial red blood cell for use in emergency and trauma care when stored blood is unavailable or in short supply. The pre-clinical stage biotech company is supported by federal grants and investor funding.
6 investors
Kano Therapeutics develops circular single-stranded DNA (cssDNA) as a genetic payload for gene-editing and other DNA-based therapies, offering an alternative to viral vectors and double-stranded DNA. It manufactures cssDNA via industrial fermentation and licenses and supplies the payload to therapeutic developers through integrated partnerships spanning discovery to GMP.
6 investors
Kopra Bio develops cancer immunotherapy technology that converts cancer cells into biofactories to produce their own destruction. The company operates in the biotech and cancer treatment space.
6 investors
Kura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.
6 investors
Labviva is an AI-native procurement platform that unifies the life sciences supply chain, helping research organizations optimize procurement processes and reduce costs. The platform serves life sciences companies and research institutions by automating lab operations and inventory management.
6 investors
Ligo develops computational tools for enzyme design by combining large language models with specialized neural networks to enable scientists and AI agents to discover new enzymes and biological functions.
6 investors
Luminate develops medical device technology to address chemotherapy side effects, particularly hair loss and peripheral neuropathy, for oncology patients and healthcare providers. The company is advancing clinical-stage devices while supporting cancer patients, clinicians, and health systems.
6 investors
Luminopia is an FDA-cleared binocular therapy for amblyopia in children aged 4-12 that uses a VR headset to stream the child's favorite TV shows as treatment, replacing traditional eye patches. Clinically tested in US trials, the therapy is prescribed by doctors and requires one hour of use per day, six days a week.
6 investors
March Bioscience is a cell therapy company assembling leading scientists and drug developers to advance cell therapy treatments. The company focuses on developing therapeutics in the cell and gene therapy space.
6 investors
Melt&Marble uses precision fermentation, microbial metabolic engineering, and synthetic biology to produce fats and ingredients aimed at creating more sustainable food products. The company develops and scales bioprocesses to translate its scientific work into large-scale, cost-effective manufacturing for the food and agri-food industry.
6 investors
Memo Therapeutics AG is a late-stage biotech company developing therapeutic antibodies for patients with viral infections and cancer. Its lead program, potravitug, is in Phase II development to treat BK polyomavirus infection in kidney transplant recipients, with additional oncology programs targeting antibodies derived from tumor-infiltrating B-cells.
6 investors
San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.
6 investors
Metsera was a clinical-stage biotechnology company developing injectable and oral medicines for obesity and metabolic diseases, including next-generation GLP-1 and amylin-based therapies. Acquired by Pfizer in 2025.
6 investors